Market News & Trends
MediciNova Announces Opening of IND for MN-166 for Prevention of Acute Respiratory Distress Syndrome in Patients With COVID-19
MediciNova, Inc. recently announced that the Investigational New Drug Application (IND) for MN-166 (ibudilast) for prevention of Acute Respiratory Distress Syndrome (ARDS) has been accepted…
Avadel Announces Sale of Hospital Sterile Injectable Drug Portfolio for $42 Million
Avadel Pharmaceuticals plc recently announced the sale of its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz, Vazculep,…
FDA Approves First & Only Oral Somatostatin Analog for Acromegaly
Chiasma, Inc. recently announced the US FDA approved MYCAPSSA (octreotide) capsules for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment…
Artelo Biosciences Expands Stony Brook Commercial License Agreement for Development of Lead Cancer, Pain & Inflammation Compounds
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today announced that it has expanded…
Intra-Cellular Therapies Announces Positive Top-line Results from Phase 1/2 Study
Intra-Cellular Therapies, Inc. recently announced topline results from Study ITI-214-104, a Phase 1/2 translational study of single ascending doses of ITI-214, a novel, selective phosphodiesterase-1…
Aptose Announces FDA Allowance of IND for Phase 1a/b Study
Aptose Biosciences Inc. recently announced the US FDA completed its review of the company’s Investigational New Drug (IND) application and has granted IND allowance for…
Oncology Venture Signs Agreement to Out-License Two Pipeline Assets
Oncology Venture A/S (OV) recently announced it has signed a definitive agreement out-licensing two clinical pipeline assets, LiPlaCis and 2X-111, to Smerud Medical Research International…
Novartis Announces MET inhibitor Approved in Japan for Advanced Non-Small Cell Lung Cancer With METex14
Novartis Pharma KK recently announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Tabrecta (capmatinib, formerly INC280), an oral MET inhibitor for…
Bormioli Pharma Invests in Type I Glass Vial Production for Injectable Medicines & Vaccines
The global, Covid-19 pandemic emergency has not weakened Bormioli Pharma's determination to keep on investing and supporting its customers. After the acquisition of the German…
Provectus Biopharmaceuticals Announces Discovery of Unique PV-10-Induced STING Pathway Mechanism
Provectus recently announce that data from ongoing preclinical study of investigational autolytic cancer immunotherapy PV-10 (rose bengal disodium) was presented at the American Association for…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….